Mycophenolate mofetil news

All news on Mycophenolate mofetil (also known as CellCept): plants, production capacities, investments and involved companies.

9 December 2025

Roche's Gazyva Approved by EU for Lupus Nephritis

Gazyva, combined with MMF, shows superior results in treating lupus nephritis, potentially delaying end-stage kidney disease, based on phase II and III studies.
28 October 2025

Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome

Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
20 October 2025

Roche's Gazyva Approved by FDA for Lupus Nephritis Treatment

FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
17 October 2025

Roche's Gazyva/Gazyvaro Gains EU CHMP Nod for Lupus Nephritis

CHMP backs Gazyva/Gazyvaro for lupus nephritis, showing superior renal response in trials. Awaiting European Commission decision.

Who will be producing Mycophenolate mofetil in the future?

Find out with chemXplore Alpha

Learn more